{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:22:08Z","timestamp":1793971328480,"version":"4.8.0"},"reference-count":53,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"crossref","award":["CRUK\/06\/019"],"award-info":[{"award-number":["CRUK\/06\/019"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CRUK_A12459"],"award-info":[{"award-number":["CRUK_A12459"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MRC_MC_UU_12023\/25"],"award-info":[{"award-number":["MRC_MC_UU_12023\/25"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Adding abiraterone acetate (AA) plus prednisolone (P) to standard of care (SOC) improves survival in newly diagnosed advanced prostate cancer (PC) patients starting hormone therapy. Our objective was to determine the value for money to the English National Health Service (NHS) of adding AAP to SOC. We used a decision analytic model to evaluate cost-effectiveness of providing AAP in the English NHS. Between 2011\u20132014, the STAMPEDE trial recruited 1917 men with high-risk localised, locally advanced, recurrent or metastatic PC starting first-line androgen-deprivation therapy (ADT), and they were randomised to receive SOC plus AAP, or SOC alone. Lifetime costs and quality-adjusted life-years (QALYs) were estimated using STAMPEDE trial data supplemented with literature data where necessary, adjusting for baseline patient and disease characteristics. British National Formulary (BNF) prices (\u00a398\/day) were applied for AAP. Costs and outcomes were discounted at 3.5%\/year. AAP was not cost-effective. The incremental cost-effectiveness ratio (ICER) was \u00a3149,748\/QALY gained in the non-metastatic (M0) subgroup, with 2.4% probability of being cost-effective at NICE\u2019s \u00a330,000\/QALY threshold; and the metastatic (M1) subgroup had an ICER of \u00a347,503\/QALY gained, with 12.0% probability of being cost-effective. Scenario analysis suggested AAP could be cost-effective in M1 patients if priced below \u00a362\/day, or below \u00a328\/day in the M0 subgroup. AAP could dominate SOC in the M0 subgroup with price below \u00a311\/day. AAP is effective for non-metastatic and metastatic disease but is not cost-effective when using the BNF price. AAP currently only has UK approval for use in a subset of M1 patients. The actual price currently paid by the English NHS for abiraterone acetate is unknown. Broadening AAP\u2019s indication and having a daily cost below the thresholds described above is recommended, given AAP improves survival in both subgroups and its cost-saving potential in M0 subgroup.<\/jats:p>","DOI":"10.1371\/journal.pone.0269192","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T17:43:28Z","timestamp":1654191808000},"page":"e0269192","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":14,"title":["Cost-utility analysis of adding abiraterone acetate plus prednisone\/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4676-1257","authenticated-orcid":true,"given":"Caroline S.","family":"Clarke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael M.","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gabrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3641-278X","authenticated-orcid":true,"given":"Christopher D.","family":"Brawley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona C.","family":"Ingleby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Dearnaley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3695-3167","authenticated-orcid":true,"given":"David","family":"Matheson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhardt","family":"Attard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9550-8808","authenticated-orcid":true,"given":"Hannah L.","family":"Rush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2904-6980","authenticated-orcid":true,"given":"Rob J.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4594-4155","authenticated-orcid":true,"given":"J. Martin","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Millman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zafar","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason F.","family":"Lester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Wylie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel W.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0166-1700","authenticated-orcid":true,"given":"Mahesh K. B.","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9323-1371","authenticated-orcid":true,"given":"Matthew R.","family":"Sydes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7314-8204","authenticated-orcid":true,"given":"Nicholas D.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"key":"pone.0269192.ref001","unstructured":"Cancer Research UK, [Online]. https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/prostate-cancer. [Accessed February 2020]."},{"key":"pone.0269192.ref002","unstructured":"World Cancer Research Fund, [Online]. https:\/\/www.wcrf.org\/dietandcancer\/cancer-trends\/prostate-cancer-statistics. [Accessed February 2020]."},{"issue":"no. 5","key":"pone.0269192.ref003","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nrc801","article-title":"A history of prostate cancer treatment","volume":"vol. 2","author":"S. R. Denmeade","year":"2002","journal-title":"Nature Reviews Cancer"},{"issue":"no. 2","key":"pone.0269192.ref004","first-page":"130","article-title":"Drugs That Offer a Survival Advantage for Men With Bone Metastases Resulting From Castration-Resistant Prostate Cancer: New and Emerging Treatment Options","volume":"vol. 39","author":"J. McCain","year":"2014","journal-title":"Pharmacy and Therapeutics"},{"key":"pone.0269192.ref005","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer","volume":"vol. 377","author":"K. Fizazi","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"pone.0269192.ref006","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1464-410X.2008.08034.x","article-title":"Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial","volume":"vol. 103","author":"N. D. James","year":"2009","journal-title":"British Journal of Urology International"},{"issue":"no. 8","key":"pone.0269192.ref007","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer","volume":"vol. 373","author":"C. J. Sweeney","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"pone.0269192.ref008","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic","volume":"vol. 14","author":"G. Gravis","year":"2013","journal-title":"Lancet Oncology"},{"key":"pone.0269192.ref009","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer","volume":"vol. 381","author":"I. D. Davis","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"no. 32","key":"pone.0269192.ref010","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy","volume":"vol. 37","author":"A. J. Armstrong","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"no. 17","key":"pone.0269192.ref011","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/jnci\/djn267","article-title":"Speeding up the Evaluation of New Agents in Cancer","volume":"vol. 100","author":"M. K. B. Parmar","year":"2008","journal-title":"Journal of the National Cancer Institute"},{"key":"pone.0269192.ref012","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy","volume":"vol. 177","author":"N. D. James","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"pone.0269192.ref013","unstructured":"Janssen-Cilag Ltd, 2020. [Online]. https:\/\/www.medicines.org.uk\/emc\/medicine\/32865. [Accessed February 2021]."},{"key":"pone.0269192.ref014","unstructured":"NICE, \u201cGuide to the methods of technology appraisal,\u201d 2013. [Online]. https:\/\/www.nice.org.uk\/process\/pmg9."},{"issue":"no. 14","key":"pone.0269192.ref015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19140","article-title":"Methods for the estimation of the NICE cost effectiveness threshold","volume":"vol. 19","author":"K. Claxton","year":"2015","journal-title":"Health Technology Assessment"},{"key":"pone.0269192.ref016","unstructured":"NICE, \u201cAbiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (TA259),\u201d National Institute for Health and Care Excellence, London, 2012, last updated 2016."},{"issue":"no. 6","key":"pone.0269192.ref017","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.euo.2019.01.004","article-title":"A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer","volume":"vol. 2","author":"N. J. Sathianathen","year":"2019","journal-title":"European Urology Oncology"},{"issue":"no. Suppl. 9","key":"pone.0269192.ref018","doi-asserted-by":"crossref","first-page":"ix69","DOI":"10.1093\/annonc\/mdz424.002","article-title":"What is the best first-line therapy for metastatic castration-sensitive prostate cancer in 2019? A network meta-analysis (202P)","volume":"vol. 30","author":"T. So","year":"2019","journal-title":"Annals of Oncology"},{"issue":"no. Suppl. 1","key":"pone.0269192.ref019","doi-asserted-by":"crossref","first-page":"A3","DOI":"10.1186\/1745-6215-12-S1-A3","article-title":"Flexible trial design in practice\u2014dropping and adding arms in STAMPEDE: a multi-arm multi-stage randomised controlled trial","volume":"vol. 12","author":"M. R. Sydes","year":"2011","journal-title":"Trials"},{"key":"pone.0269192.ref020","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/1745-6215-13-168","article-title":"Flexible trial design in practice\u2014stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial","volume":"vol. 13","author":"M. R. Sydes","year":"2012","journal-title":"Trials"},{"issue":"no. 4","key":"pone.0269192.ref021","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2020.01.012","article-title":"Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019","volume":"vol. 77","author":"S. Gillessen","year":"2020","journal-title":"European Urology"},{"key":"pone.0269192.ref022","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.euo.2018.06.004","article-title":"Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness","author":"B. S. Woods","year":"2018","journal-title":"European Urology Oncology"},{"issue":"no. 3","key":"pone.0269192.ref023","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/jamaoncol.2015.4350","article-title":"Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer. Data from patients in the control arm of the STAMPEDE trial","volume":"vol. 2","author":"N. D. James","year":"2016","journal-title":"JAMA Oncology"},{"key":"pone.0269192.ref024","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.eururo.2014.09.032","article-title":"Survival with newly diagnosed metastatic prostate cancer in the \u201cdocetaxel era\u201d: data from 917 patients in the control arm of the STAMPEDE trial","volume":"vol. 67","author":"N. D. James","year":"2015","journal-title":"European Urology"},{"issue":"no. 6","key":"pone.0269192.ref025","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0272989X12472398","article-title":"Survival Analysis for Economic Evaluations Alongside Clinical Trials\u2014Extrapolation with Patient-Level Data: Inconsistencies, Limitations, and a Practical Guide","volume":"vol. 33","author":"N. Latimer","year":"2013","journal-title":"Medical Decision Making"},{"issue":"no. 4","key":"pone.0269192.ref026","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/0272989X16651869","article-title":"Cost-Effectiveness Analysis in R Using a Multi-state Modeling Survival Analysis Framework: A Tutorial","volume":"vol. 37","author":"C. Williams","year":"2016","journal-title":"Medical Decision Making"},{"issue":"no. 1","key":"pone.0269192.ref027","doi-asserted-by":"crossref","DOI":"10.18637\/jss.v038.i01","article-title":"Special Issue about Competing Risks and Multi-State Models","volume":"vol. 38","author":"H. Putter","year":"2011","journal-title":"Journal of Statistical Software"},{"issue":"no. 3","key":"pone.0269192.ref028","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/bimj.200510218","article-title":"Estimation and Prediction in a Multi-State Model for Breast Cancer","volume":"vol. 48","author":"H. Putter","year":"2006","journal-title":"Biometrical Journal"},{"key":"pone.0269192.ref029","unstructured":"NICE, \u201cAbiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387),\u201d National Institute for Health and Care Excellence, London, 2016."},{"key":"pone.0269192.ref030","unstructured":"H. Akaike, \u201cInformation theory and an extension of the maximum likelihood principle,\u201d in Second International Symposium on Information Theory, B. N. Petrov and B. F. Csaki, Eds., Budapest, Academiai Kiado, 1973, pp. 267\u2013281."},{"key":"pone.0269192.ref031","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modelling valuations for EuroQol health states","volume":"vol. 35","author":"P. Dolan","year":"1997","journal-title":"Medical Care"},{"key":"pone.0269192.ref032","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s11136-014-0837-y","article-title":"Multiple imputation to deal with missing EQ-5D-3L data: Should we impute individual domains or the actual index?","volume":"vol. 24","author":"C. L. Simons","year":"2015","journal-title":"Quality of Life Research"},{"issue":"no. 3","key":"pone.0269192.ref033","first-page":"1","article-title":"mice: Multivariate Imputation by Chained","volume":"vol. 45","author":"S. van Buuren","year":"2011","journal-title":"Journal of Statistical Software"},{"issue":"no. 1","key":"pone.0269192.ref034","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.0006-341X.2001.00120.x","article-title":"Akaike\u2019s information criterion in generalized estimating equations","volume":"vol. 57","author":"W. Pan","year":"2001","journal-title":"Biometrics"},{"issue":"no. 1","key":"pone.0269192.ref035","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/0272989X11416988","article-title":"Regression estimators for generic health-related quality of life and quality-adjusted life years","volume":"vol. 21","author":"A. Basu","year":"2012","journal-title":"Medical Decision Making"},{"key":"pone.0269192.ref036","unstructured":"Joint Formulary Committee, \u201cBritish National Formulary (online),\u201d London."},{"key":"pone.0269192.ref037","unstructured":"L. Curtis and A. Burns, \u201cUnit Costs of Health and Social Care 2018,\u201d Personal Social Services Research Unit, University of Kent, Canterbury, 2018."},{"key":"pone.0269192.ref038","unstructured":"L. Curtis and A. Burns, \u201cUnit Costs of Health and Social Care 2015,\u201d Personal Social Services Research Unit, University of Kent, Canterbury, 2015."},{"key":"pone.0269192.ref039","unstructured":"R Core Team, R: A language and environment for statistical computing, Vienna: R Foundation for Statistical Computing, 2020."},{"key":"pone.0269192.ref040","unstructured":"Office for National Statistics, \u201cLife Tables,\u201d 2018."},{"issue":"no. 2","key":"pone.0269192.ref041","first-page":"1057","article-title":"Predictive factors for response to abiraterone in metastatic castration refractory prostate cancer","volume":"vol. 35","author":"M. Afshar","year":"2015","journal-title":"Anticancer Research"},{"key":"pone.0269192.ref042","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/hec.635","article-title":"Representing uncertainty: the role of cost-effectiveness acceptability curves","volume":"vol. 10","author":"E. Fenwick","year":"2001","journal-title":"Health Economics"},{"issue":"no. 4","key":"pone.0269192.ref043","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40273-014-0247-6","article-title":"An Educational Review of the Statistical Issues in Analysing Utility Data for Cost-Utility Analysis","volume":"vol. 33","author":"R. M. Hunter","year":"2015","journal-title":"PharmacoEconomics"},{"issue":"no. 10","key":"pone.0269192.ref044","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/0269216315595203","article-title":"Estimating the cost of caring for people with cancer at the end of life: A modelling study","volume":"vol. 29","author":"J. Round","year":"2015","journal-title":"Palliative Medicine"},{"key":"pone.0269192.ref045","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jval.2013.02.010","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement","volume":"vol. 16","author":"D. Husereau","year":"2013","journal-title":"Value in Health"},{"key":"pone.0269192.ref046","unstructured":"StataCorp, Stata Statistical Software: Release 14, College Station, TX, USA: StataCorp LP, 2015."},{"key":"pone.0269192.ref047","unstructured":"StataCorp, Stata Statistical Software: Release 16, College Station, TX, USA: StataCorp LP, 2019."},{"issue":"no. 2","key":"pone.0269192.ref048","first-page":"111","article-title":"Prostate Cancer in Elderly Men","volume":"vol. 10","author":"A. Stangelberger","year":"2008","journal-title":"Reviews in Urology"},{"key":"pone.0269192.ref049","doi-asserted-by":"crossref","first-page":"627083","DOI":"10.3389\/fonc.2021.627083","article-title":"A Cost-Effectiveness Analysis of Systemic Therapy for Metastatic Hormone-Sensitive Prostate Cancer","volume":"vol. 11","author":"W. W. Sung","year":"2021","journal-title":"Frontiers in Oncology"},{"key":"pone.0269192.ref050","unstructured":"National Prostate Cancer Audit, \u201cAnnual Report 2019: Results of the NPCA Prospective Audit in England and Wales for men diagnosed from 1 April 2017 to 31 March 2018 (published January 2020),\u201d 21 February 2020. [Online]. https:\/\/www.npca.org.uk\/content\/uploads\/2020\/01\/NPCA-Annual-Report-2019_090120.pdf. [Accessed December 2020]."},{"issue":"no. 14","key":"pone.0269192.ref051","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1200\/JCO.2017.76.4381","article-title":"Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer","volume":"vol. 36","author":"R. Z. Szmulewitz","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"no. 30","key":"pone.0269192.ref052","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1200\/JCO.2018.79.2358","article-title":"Low-Fat Abiraterone Food Effect Is of Great Consequence","volume":"vol. 36","author":"I. F. Tannock","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"pone.0269192.ref053","unstructured":"NICE, \u201cAbiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (TA721),\u201d National Institute for Health and Care Excellence, London, 2021"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0269192","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T17:44:18Z","timestamp":1654191858000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0269192"}},"subtitle":[],"editor":[{"given":"Giandomenico","family":"Roviello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,6,2]]},"references-count":53,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0269192","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,2]]}}}